Completed OBSERVATIONAL NCT02663232

Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma

Epidemiological Study of V600 BRAF Mutation in Spanish Patients Diagnosed With Metastatic Melanoma: ABSOLUT-BRAF Study

Sponsor: Hoffmann-La Roche

Updated 10 times since 2017 Last updated: Jun 29, 2023 Started: Jun 30, 2013 Primary completion: Oct 31, 2014 Completion: Oct 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Metastatic Cancers and is currently completed. Hoffmann-La Roche leads this study, which shows 10 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Aug 2023 — Jul 2024 [monthly]

Completed
Jan 2023 — Aug 2023 [monthly]

Completed

▶ Show 5 earlier versions

Dec 2022 — Jan 2023 [monthly]

Completed
Jan 2021 — Dec 2022 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jun 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Barcelona, Spain , Bilbao, Spain , Burgos, Spain , Cartagena (Murcia), Spain , Castellon, Spain , Cáceres, Spain , Donostia / San Sebastian, Spain , Girona, Spain , Granada, Spain and 15 more locations